Terms: = Bone cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
65 results:
1. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
[TBL] [Abstract] [Full Text] [Related]
2. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced nras-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract] [Full Text] [Related]
3. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Ejerblad E; Olesen G; Björklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Yip Lundström L; von Bahr L; Baltzer-Sollander K; Jädersten M; Kytölä S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellström-Lindberg E
J Clin Oncol; 2024 Apr; 42(12):1378-1390. PubMed ID: 38232336
[TBL] [Abstract] [Full Text] [Related]
4. RAS‑stimulated release of exosomal
Kim O; Tran PT; Gal M; Lee SJ; Na SH; Hwangbo C; Lee JH
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37503759
[TBL] [Abstract] [Full Text] [Related]
5. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
[TBL] [Abstract] [Full Text] [Related]
6. A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.
Morris VS; Ghazi H; Fletcher DM; Guinn BA
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298623
[TBL] [Abstract] [Full Text] [Related]
7. Acute Lymphoblastic Leukemia Developing in a Patient with 46, XY Pure Gonadal Dysgenesis (Swyer Syndrome) with Malignant Gonadal Germ Cell Tumor: A Case Report and Literature Review.
Zhang X; Zhang Y; Wang J; Yang J; Yu S; Yin M; Li S; Yang J
Curr Oncol; 2022 Dec; 29(12):9753-9759. PubMed ID: 36547180
[TBL] [Abstract] [Full Text] [Related]
8. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Stahl M; Derkach A; Farnoud N; Bewersdorf JP; Robinson T; Famulare C; Cho C; Devlin S; Menghrajani K; Patel MA; Cai SF; Miles LA; Bowman RL; Geyer MB; Dunbar A; Epstein-Peterson ZD; McGovern E; Schulman J; Glass JL; Taylor J; Viny AD; Stein EM; Getta B; Arcila ME; Gao Q; Barker J; Shaffer BC; Papadopoulos EB; Gyurkocza B; Perales MA; Abdel-Wahab O; Levine RL; Giralt SA; Zhang Y; Xiao W; Pai N; Papaemmanuil E; Tallman MS; Roshal M; Goldberg AD
Am J Hematol; 2023 Jan; 98(1):79-89. PubMed ID: 36251406
[TBL] [Abstract] [Full Text] [Related]
9. Successful treatment with MEK-inhibitor in a patient with nras-related cutaneous skeletal hypophosphatemia syndrome.
Carli D; Cardaropoli S; Tessaris D; Coppo P; La Selva R; Cesario C; Lepri FR; Pullano V; Palumbo M; Ramenghi U; Brusco A; Medico E; De Sanctis L; Ferrero GB; Mussa A
Genes Chromosomes Cancer; 2022 Dec; 61(12):740-746. PubMed ID: 35999193
[TBL] [Abstract] [Full Text] [Related]
10. Diagnosis and treatment of nail melanoma: a review of the clinicopathologic, dermoscopic, and genetic characteristics.
Darmawan CC; Ohn J; Mun JH; Kim S; Lim Y; Jo SJ; Kim YG; Kim B; Seong MW; Kim BJ; Lee C; Kwak Y; Chung HJ; Virós A; Lee DY
J Eur Acad Dermatol Venereol; 2022 May; 36(5):651-660. PubMed ID: 35098589
[TBL] [Abstract] [Full Text] [Related]
11. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract] [Full Text] [Related]
12. Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data.
Zhang X; Jin F; Jiang S; Cao J; Meng Y; Xu Y; ChunmengWang ; Chen Y; Yang H; Kong Y; Liu X; Luo Z
Invest New Drugs; 2022 Apr; 40(2):453-460. PubMed ID: 34731354
[TBL] [Abstract] [Full Text] [Related]
13. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
Park HS; Son BR; Shin KS; Byeon S; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
Acta Haematol; 2021; 144(6):649-659. PubMed ID: 34233332
[TBL] [Abstract] [Full Text] [Related]
14. Mixed phenotype acute leukemia in a child associated with a NUP98-NSD1 fusion and nras p.Gly61Arg mutation.
Ganapathi SS; Raikar SS; Yatsenko SA; Djokic M; Bukowinski A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1372. PubMed ID: 33784031
[TBL] [Abstract] [Full Text] [Related]
15. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation.
Gagelmann N; Badbaran A; Beelen DW; Salit RB; Stölzel F; Rautenberg C; Becker H; Radujkovic A; Panagiota V; Bogdanov R; Christopeit M; Park Y; Nibourel O; Luft T; Koldehoff M; Corsten M; Heuser M; Finke J; Kobbe G; Platzbecker U; Robin M; Scott BL; Kröger N
Blood Adv; 2021 Mar; 5(6):1760-1769. PubMed ID: 33755092
[TBL] [Abstract] [Full Text] [Related]
16. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
Ariyasu R; Uchibori K; Sasaki T; Tsukahara M; Kiyotani K; Yoshida R; Ono Y; Kitazono S; Ninomiya H; Ishikawa Y; Mizukami Y; Yanagitani N; Fujita N; Nishio M; Katayama R
Cancer Sci; 2021 Jun; 112(6):2371-2380. PubMed ID: 33686722
[TBL] [Abstract] [Full Text] [Related]
17. Differential Outcomes in Codon 12/13 and Codon 61
Cleary JM; Wang V; Heist RS; Kopetz ES; Mitchell EP; Zwiebel JA; Kapner KS; Chen HX; Li S; Gray RJ; McShane LM; Rubinstein LV; Patton DR; Meric-Bernstam F; Dillmon MS; Williams PM; Hamilton SR; Conley BA; Aguirre AJ; O'Dwyer PJ; Harris LN; Arteaga CL; Chen AP; Flaherty KT
Clin Cancer Res; 2021 Jun; 27(11):2996-3004. PubMed ID: 33637626
[TBL] [Abstract] [Full Text] [Related]
18. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
[TBL] [Abstract] [Full Text] [Related]
19. TP-0903 is active in models of drug-resistant acute myeloid leukemia.
Jeon JY; Buelow DR; Garrison DA; Niu M; Eisenmann ED; Huang KM; Zavorka Thomas ME; Weber RH; Whatcott CJ; Warner SL; Orwick SJ; Carmichael B; Stahl E; Brinton LT; Lapalombella R; Blachly JS; Hertlein E; Byrd JC; Bhatnagar B; Baker SD
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33268594
[TBL] [Abstract] [Full Text] [Related]
20. In vivo antitumoral effect of 4-nerolidylcatechol (4-NC) in nras-mutant human melanoma.
Alves-Fernandes DK; Oliveira ÉA; Hastreiter AA; Faião-Flores F; Felipe-Silva AS; Turato W; Fock RA; Maria-Engler SS; Barros SBM
Food Chem Toxicol; 2020 Jul; 141():111371. PubMed ID: 32334110
[TBL] [Abstract] [Full Text] [Related]
[Next]